{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:46:00Z","timestamp":1740141960449,"version":"3.37.3"},"reference-count":68,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["18-15-00254"],"award-info":[{"award-number":["18-15-00254"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2020,7,15]]},"abstract":"<jats:sec><jats:title\/><jats:p>Atherosclerosis is a chronic arterial disease characterized by vascular inflammation, accumulation of lipids in the arterial wall, and formation and growth of atherosclerotic plaques followed by ischemia. In subclinical atherosclerosis, cholesterol retention in subendothelial cells leads to induction of local inflammation, generation of foam cells and lesion formation, followed by a chain of other pathogenic events. Atherosclerotic progression can frequently be fatal, since plaque rupture may lead to thrombosis and acute events, such as myocardial infarction, stroke and sudden death. Traditional anti-atherosclerotic therapy is mainly focused on improving the blood lipid profile and does not target various stages of plaque progression. Obviously, treating the disease at initial stages is better than beginning treatment at advanced stages and, in that regard, current atherosclerosis management can be improved. Cholesterol retention is an important component of atherogenesis that precedes plaque formation. Therapeutic targeting of cholesterol retention may be beneficial for preventing further atherogenic progression. For this purpose, we suggest using herbal preparations due to good tolerability and suitability for long-lasting treatment. We developed test systems based on cultured human intimal aortic cells for rapid screening of potential anti-atherogenic drugs. With the help of these test systems, we selected several natural substances with significant anti-atherogenic activity and further use these compounds to prepare herbal preparations for anti-atherosclerotic therapy. These preparations were clinically tested and showed good safety and a potent anti-atherogenic potential.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570163816666190101112241","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T07:00:32Z","timestamp":1547017232000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review of Our Own Data)"],"prefix":"10.2174","volume":"17","author":[{"given":"Alexander N.","family":"Orekhov","sequence":"first","affiliation":[{"name":"Federal Scientific Clinical Center for Resuscitation and Rehabilitation, 109240 Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey V.","family":"Grechko","sequence":"additional","affiliation":[{"name":"Federal Scientific Clinical Center for Resuscitation and Rehabilitation, 109240 Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena B.","family":"Romanenko","sequence":"additional","affiliation":[{"name":"Department of Molecular Basis of Ontogenesis, Belozersky Institute of Physical and Chemical Biology, Moscow State University, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitry A.","family":"Chistiakov","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Division of Basic and Applied Neurobiology, Serbsky Federal Medical Research Center of Psychiatry and Narcology, 119991 Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"163","volume":"1","author":"Orekhov,A. .","year":"2017","unstructured":"Orekhov,A.; Ivanova,E. Introduction of the special issue Athero-sclerosis and Related Diseases. Vessel Plus. 2017; 1: 163-5","journal-title":"Vessel Plus"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(97) 00161-5","volume":"135(1)","author":"Finking,G.","year":"1997","unstructured":"Finking,G.; Hanke,H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for athero-sclerosis research. Atherosclerosis. 1997; 135(1): 1-7. http:\/\/dx.doi.org\/10.1016\/S0021-9150(97) 00161-5 PMID: 9395267","journal-title":"Atherosclerosis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1161\/ATVBAHA.112.300133","volume":"32(12)","author":"Fisher,EA.","year":"2012","unstructured":"Fisher,EA.; Feig,JE.; Hewing,B.; Hazen,SL.; Smith,JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012; 32(12): 2813-20. http:\/\/dx.doi.org\/10.1161\/ATVBAHA.112.300133 PMID: 23152494","journal-title":"Arterioscler Thromb Vasc Biol"},{"author":"Alipov,V.","key":"ref=4","doi-asserted-by":"publisher","unstructured":"Alipov,V.; Sukhorukov,V.; Karagodin,V.; Grechko,A.; Orekhov,A. Chemical composition of circulating native and desialylated low density lipoprotein: What is the difference? Vessel Plus. 2017; 1: 107-15. http:\/\/dx.doi.org\/10.20517\/2574-1209.2017.20","DOI":"10.20517\/2574-1209.2017.20"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.20517\/2574-1209.2016.12","volume":"1","author":"Sobenin,I.","year":"2017","unstructured":"Sobenin,I.; Galitsyna,E.; Grechko,A.; Orekhov,A. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel Plus. 2017; 1: 29-37. http:\/\/dx.doi.org\/10.20517\/2574-1209.2016.12","journal-title":"Vessel Plus"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.20517\/2574-1209.2017.27","volume":"1","author":"Harangi,M.","year":"2017","unstructured":"Harangi M, Szentp?teri A, N?dr? B.;et al. HDL subfraction distri-bution and HDL function in untreated dyslipidemic patients. Vessel Plus. 2017; 1: 166-73. http:\/\/dx.doi.org\/10.20517\/2574-1209.2017.27","journal-title":"Vessel Plus"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","volume":"116(16)","author":"Tabas,I.","year":"2007","unstructured":"Tabas,I.; Williams,KJ.; Bor?n,J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116(16): 1832-44. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.106.676890 PMID: 17938300","journal-title":"Circulation"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00041433-200410000-00003","volume":"15(5)","author":"Gustafsson,M.","year":"2004","unstructured":"Gustafsson,M.; Bor?n,J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol. 2004; 15(5): 505-14. http:\/\/dx.doi.org\/10.1097\/00041433-200410000-00003 PMID: 15361785","journal-title":"Curr Opin Lipidol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00041433-200210000-00001","volume":"13(5)","author":"Proctor,SD.","year":"2002","unstructured":"Proctor,SD.; Vine,DF.; Mamo,JC. Arterial retention of apolipopro-tein B(48)-and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002; 13(5): 461-70. http:\/\/dx.doi.org\/10.1097\/00041433-200210000-00001 PMID: 12352009","journal-title":"Curr Opin Lipidol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"0","DOI":"10.20517\/2574-1209.2017.21","volume":"1","author":"Nikiforov,N.","year":"2017","unstructured":"Nikiforov,N.; Galstyan,K.; Nedosugova,L.; Elizova,N.; Kolmychkova,K.; Ivanova,E. Proinflammatory monocyte polarization in type 2 di-abetes mellitus and coronary heart disease. Vessel Plus. 2017; 1: 0. http:\/\/dx.doi.org\/10.20517\/2574-1209.2017.21","journal-title":"Vessel Plus"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/MOL.0000000000000279","volume":"27(2)","author":"Dubland,JA.","year":"2016","unstructured":"Dubland,JA.; Francis,GA. So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation. Curr Opin Lipidol. 2016; 27(2): 155-61. http:\/\/dx.doi.org\/10.1097\/MOL.0000000000000279 PMID: 26836481","journal-title":"Curr Opin Lipidol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.carpath.2012.06.006","volume":"22(1)","author":"Gimbrone,MA,Jr.","year":"2013","unstructured":"Gimbrone,MA,Jr.; Garc?a-Carde?a,G. Vascular endothelium, he-modynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol. 2013; 22(1): 9-15. http:\/\/dx.doi.org\/10.1016\/j.carpath.2012.06.006 PMID: 22818581","journal-title":"Cardiovasc Pathol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"11324","DOI":"10.3390\/ijms150711324","volume":"15(7)","author":"Steyers,CM,III.","year":"2014","unstructured":"Steyers,CM,III.; Miller,FJ,Jr. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014; 15(7): 11324-49. http:\/\/dx.doi.org\/10.3390\/ijms150711324 PMID: 24968272","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e0163988","DOI":"10.1371\/journal.pone.0163988","volume":"11(10)","author":"Magalhaes,A.","year":"2016","unstructured":"Magalhaes,A.; Matias,I.; Palmela,I.; Brito,MA.; Dias,S. LDL-cholesterol increases the transcytosis of molecules through endo-thelial monolayers. PLoS One. 2016; 11(10): e0163988 http:\/\/dx.doi.org\/10.1371\/journal.pone.0163988 PMID: 27695052","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0741-5214(93) 90033-I","volume":"17(5)","author":"Alexander,JJ.","year":"1993","unstructured":"Alexander,JJ.; Miguel,R.; Piotrowski,JJ. The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space. J Vasc Surg. 1993; 17(5): 841-7. http:\/\/dx.doi.org\/10.1016\/0741-5214(93) 90033-I PMID: 8487352","journal-title":"J Vasc Surg"},{"key":"ref=16","first-page":"233","volume":"13(5)","author":"Orekhov,AN.","year":"1991","unstructured":"Orekhov,AN.; Kalenich,OS.; Tertov,VV.; Novikov,ID. Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue Re-act. 1991; 13(5): 233-6. PMID: 1806545","journal-title":"Int J Tissue Re-act"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00019501-199304000-00010","volume":"4(4)","author":"Jaakkola,O.","year":"1993","unstructured":"Jaakkola,O.; Solakivi,T.; Tertov,VV.; Orekhov,AN.; Miettinen,TA.; Nikkari,T. Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease. Coron Artery Dis. 1993; 4(4): 379-85. http:\/\/dx.doi.org\/10.1097\/00019501-199304000-00010 PMID: 8261211","journal-title":"Coron Artery Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/07853890.1993.12088583","volume":"25(6)","author":"Kacharava,AG.","year":"1993","unstructured":"Kacharava,AG.; Tertov,VV.; Orekhov,AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med. 1993; 25(6): 551-5. http:\/\/dx.doi.org\/10.1080\/07853890.1993.12088583 PMID: 8292305","journal-title":"Ann Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exmp.1997.2216","volume":"64(3)","author":"Tertov,VV.","year":"1997","unstructured":"Tertov,VV.; Orekhov,AN. Metabolism of native and naturally oc-curring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp Mol Pathol. 1997; 64(3): 127-45. http:\/\/dx.doi.org\/10.1006\/exmp.1997.2216 PMID: 9439479","journal-title":"Exp Mol Pathol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"463797","DOI":"10.1155\/2015\/463797","volume":"2015","author":"Orekhov,AN.","year":"2015","unstructured":"Orekhov,AN.; Sobenin,IA.; Revin,VV.; Bobryshev,YV. Develop-ment of antiatherosclerotic drugs on the basis of natural products using cell model approach. Oxid Med Cell Longev. 2015; 2015: 463797. http:\/\/dx.doi.org\/10.1155\/2015\/463797 PMID: 26347804","journal-title":"Oxid Med Cell Longev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0006-291X(89) 91982-7","volume":"162(1)","author":"Orekhov,AN.","year":"1989","unstructured":"Orekhov,AN.; Tertov,VV.; Mukhin,DN.; Mikhailenko,IA. Modifica-tion of low density lipoprotein by desialylation causes lipid accu-mulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic pa-tients. Biochem Biophys Res Commun. 1989; 162(1): 206-11. http:\/\/dx.doi.org\/10.1016\/0006-291X(89) 91982-7 PMID: 2751649","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0006-291X(89) 92163-3","volume":"163(1)","author":"Tertov,VV.","year":"1989","unstructured":"Tertov,VV.; Sobenin,IA.; Gabbasov,ZA.; Popov,EG.; Orekhov,AN. Lipoprotein aggregation as an essential condition of intracellular li-pid accumulation caused by modified low density lipoproteins. Bi-ochem Biophys Res Commun. 1989; 163(1): 489-94. http:\/\/dx.doi.org\/10.1016\/0006-291X(89) 92163-3 PMID: 2775281","journal-title":"Bi-ochem Biophys Res Commun"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/0006-291X(90) 90639-5","volume":"167(3)","author":"Tertov,VV.","year":"1990","unstructured":"Tertov,VV.; Sobenin,IA.; Tonevits,ky,AG.; Orekhov,AN.; Smirnov,VN. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun. 1990; 167(3): 1122-7. http:\/\/dx.doi.org\/10.1016\/0006-291X(90) 90639-5 PMID: 2322261","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/10715769609149054","volume":"25(4)","author":"Tertov,VV.","year":"1996","unstructured":"Tertov,VV.; Sobenin,IA.; Orekhov,AN. Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Free Radic Res. 1996; 25(4): 313-9. http:\/\/dx.doi.org\/10.3109\/10715769609149054 PMID: 8889495","journal-title":"Free Radic Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0021-9150(01) 00498-1","volume":"159(1)","author":"Tertov,VV.","year":"2001","unstructured":"Tertov,VV.; Kaplun,VV.; Sobenin,IA.; Boytsova,EY.; Bovin,NV.; Orekhov,AN. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis. 2001; 159(1): 103-15. http:\/\/dx.doi.org\/10.1016\/S0021-9150(01) 00498-1 PMID: 11689212","journal-title":"Atherosclerosis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1023\/A:1019918704920","volume":"67(8)","author":"Tertov,VV.","year":"2002","unstructured":"Tertov,VV.; Nikonova,EY.; Nifant?ev,NE.; Bovin,NV.; Orekhov,AN. Human plasma trans-sialidase donor and acceptor specificity. Bio-chemistry (Mosc). 2002; 67(8): 908-13. http:\/\/dx.doi.org\/10.1023\/A:1019918704920 PMID: 12223090","journal-title":"Bio-chemistry (Mosc)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1016\/j.bmcl.2004.07.058","volume":"14(20)","author":"Nikonova,EY.","year":"2004","unstructured":"Nikonova,EY.; Tertov,VV.; Sato,C.; Kitajima,K.; Bovin,NV. Speci-ficity of human trans-sialidase as probed with gangliosides. Bioorg Med Chem Lett. 2004; 14(20): 5161-4. http:\/\/dx.doi.org\/10.1016\/j.bmcl.2004.07.058 PMID: 15380219","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1590\/S0066-782X2003000900001","author":"Higuchi,MdeL.","unstructured":"Higuchi MdeL, Reis MM, Sambiase NV.;et al. Coinfection with Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured plaques associated with acute myocardial infarction. Arq Bras Car-diol. 2003; 81(1): 12-22,1-11. http:\/\/dx.doi.org\/10.1590\/S0066-782X2003000900001 PMID: 12908069","journal-title":"Arq Bras Car-diol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2004.04.019","volume":"176(1)","author":"Momiyama,Y.","year":"2004","unstructured":"Momiyama,Y.; Ohmori,R.; Taniguchi,H.; Nakamura,H.; Ohsuzu,F. Association of Mycoplasma pneumoniae infection with coronary artery disease and its interaction with chlamydial infection. Athero-sclerosis. 2004; 176(1): 139-44. http:\/\/dx.doi.org\/10.1016\/j.atherosclerosis.2004.04.019 PMID: 15306186","journal-title":"Athero-sclerosis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7212985","DOI":"10.1155\/2017\/7212985","volume":"2017","author":"Garavelo,SM.","year":"2017","unstructured":"Garavelo SM, Higuchi ML, Pereira JJ.;et al. Comparison of the protective effects of individual components of particulated trans-Sialidase (PTCTS),PTC and TS, Against High Cholesterol Diet-Induced Atherosclerosis in Rabbits. BioMed Res Int. 2017; 2017: 7212985. http:\/\/dx.doi.org\/10.1155\/2017\/7212985 PMID: 28337456","journal-title":"BioMed Res Int"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-2275(20)38178-5","volume":"23(1)","author":"Krauss,RM.","year":"1982","unstructured":"Krauss,RM.; Burke,DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982; 23(1): 97-104. PMID: 7057116","journal-title":"J Lipid Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1161\/01.ATV.8.1.79","volume":"8(1)","author":"Avogaro,P.","year":"1988","unstructured":"Avogaro,P.; Bon,GB.; Cazzolato,G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 1988; 8(1): 79-87. http:\/\/dx.doi.org\/10.1161\/01.ATV.8.1.79 PMID: 3341993","journal-title":"Arteriosclerosis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1006\/exmp.1995.1018","volume":"62(3)","author":"Tertov,VV.","year":"1995","unstructured":"Tertov,VV.; Bittolo-Bon,G.; Sobenin,IA.; Cazzolato,G.; Orekhov,AN.; Avogaro,P. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol. 1995; 62(3): 166-72. http:\/\/dx.doi.org\/10.1006\/exmp.1995.1018 PMID: 8612720","journal-title":"Exp Mol Pathol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0021-9150(91) 90211-K","volume":"86(2-3)","author":"Orekhov,AN.","year":"1991","unstructured":"Orekhov,AN.; Tertov,VV.; Mukhin,DN. Desialylated low density lipoprotein-naturally occurring modified lipoprotein with athero-genic potency. Atherosclerosis. 1991; 86(2-3): 153-61. http:\/\/dx.doi.org\/10.1016\/0021-9150(91) 90211-K PMID: 1872910","journal-title":"Atherosclerosis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0021-9150(95) 05737-4","volume":"122(2)","author":"Tertov,VV.","year":"1996","unstructured":"Tertov,VV.; Sobenin,IA.; Orekhov,AN.; Jaakkola,O.; Sola,kivi,T.; Nikkari,T. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis. 1996; 122(2): 191-9. http:\/\/dx.doi.org\/10.1016\/0021-9150(95) 05737-4 PMID: 8769682","journal-title":"Atherosclerosis"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0022-2275(20)42342-9","volume":"31(9)","author":"La,Belle,M.","year":"1990","unstructured":"La Belle,M.; Krauss,RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res. 1990; 31(9): 1577-88. PMID: 2246611","journal-title":"J Lipid Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"12807","DOI":"10.3390\/ijms150712807","volume":"15(7)","author":"Orekhov,AN.","year":"2014","unstructured":"Orekhov,AN.; Bobryshev,YV.; Sobenin,IA.; Melnichenko,AA.; Chistiakov,DA. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prog-nostic biomarkers of atherosclerosis and type 1 diabetes macrovas-cular disease. Int J Mol Sci. 2014; 15(7): 12807-41. http:\/\/dx.doi.org\/10.3390\/ijms150712807 PMID: 25050779","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.imbio.2012.01.008","volume":"217(5)","author":"Gratchev,A.","year":"2012","unstructured":"Gratchev,A.; Sobenin,I.; Orekhov,A.; Kzhyshkowska,J. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology. 2012; 217(5): 476-82. http:\/\/dx.doi.org\/10.1016\/j.imbio.2012.01.008 PMID: 22325375","journal-title":"Immunobiology"},{"key":"ref=39","first-page":"395","volume":"48(4)","author":"Orekhov,AN.","year":"1983","unstructured":"Orekhov,AN.; Kosykh,VA.; Repin,VS.; Smirnov,VN. Cell prolifera-tion in normal and atherosclerotic human aorta, I. Flow cytofluo-rometric determination of cellular deoxyribonucleic acid content. Lab Invest. 1983; 48(4): 395-8. PMID: 6834785","journal-title":"Lab Invest"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1365-2567.2003.01694.x","volume":"109(4)","author":"Maldonado,A.","year":"2003","unstructured":"Maldonado,A.; Game,BA.; Song,L.; Huang,Y. Up-regulation of matrix metalloproteinase-1 expression in U937 cells by low-density lipoprotein-containing immune complexes requires the activator protein-1 and the Ets motifs in the distal and the proximal promoter regions. Immunology. 2003; 109(4): 572-9. http:\/\/dx.doi.org\/10.1046\/j.1365-2567.2003.01694.x PMID: 12871225","journal-title":"Immunology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(86) 92426-8","volume":"2(8507)","author":"Chazov,EI.","year":"1986","unstructured":"Chazov EI, Tertov VV, Orekhov AN.;et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet. 1986; 2(8507): 595-8. http:\/\/dx.doi.org\/10.1016\/S0140-6736(86) 92426-8 PMID: 2875319","journal-title":"Lancet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0014-4800(85) 90022-X","volume":"42(1)","author":"Orekhov,AN.","year":"1985","unstructured":"Orekhov AN, Tertov VV, Novikov ID.;et al. Lipids in cells of atherosclerotic and uninvolved human aorta, I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells. Exp Mol Pathol. 1985; 42(1): 117-37. http:\/\/dx.doi.org\/10.1016\/0014-4800(85) 90022-X PMID: 3967748","journal-title":"Exp Mol Pathol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0021-9150(86) 90002-X","volume":"60(2)","author":"Orekhov,AN.","year":"1986","unstructured":"Orekhov,AN.; Tertov,VV.; Kudryashov,SA.; Khashimov KhA.; Smirnov,VN. Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis. 1986; 60(2): 101-10. http:\/\/dx.doi.org\/10.1016\/0021-9150(86) 90002-X PMID: 3013216","journal-title":"Atherosclerosis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/BF00746043","volume":"11","author":"Corsini,A.","year":"1993","unstructured":"Corsini A, Grignaffini P, Beitz J.;et al. Effect of trapidil derivative AR 12456 on intracellular cholesterol homeostasis in human hepa-toma cell line Hep G2. Cytotechnology. 1993; 11: S15-7. http:\/\/dx.doi.org\/10.1007\/BF00746043","journal-title":"Cytotechnology"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/01.ATV.17.5.979","volume":"17(5)","author":"Lesnik,P.","year":"1997","unstructured":"Lesnik P, Dachet C, Petit L.;et al. Impact of a combination of a calcium antagonist and a beta-blocker on cell-and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol. 1997; 17(5): 979-88. http:\/\/dx.doi.org\/10.1161\/01.ATV.17.5.979 PMID: 9157964","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(84) 91574-5","volume":"2(8412)","author":"Orekhov,AN.","year":"1984","unstructured":"Orekhov AN, Misharin AYu, Tertov VV.;et al. Artificial HDL as an anti-atherosclerotic drug. Lancet. 1984; 2(8412): 1149-50. http:\/\/dx.doi.org\/10.1016\/S0140-6736(84) 91574-5 PMID: 6150198","journal-title":"Lancet"},{"key":"ref=47","first-page":"S286","volume":"47(10-11)","author":"Tertov,VV.","year":"1988","unstructured":"Tertov,VV.; Panosyan,AG.; Akopov,SE.; Orekhov,AN. The effects of eicozanoids and lipoxygenase inhibitors on the lipid metabolism of aortic cells. Biomed Biochim Acta. 1988; 47(10-11): S286-8. PMID: 3150271","journal-title":"Biomed Biochim Acta"},{"key":"ref=48","first-page":"538","volume":"37(5)","author":"Giessler,C.","year":"1987","unstructured":"Giessler C, Fahr A, Tertov VV.;et al. Trapidil derivatives as poten-tial antiatherosclerotic drugs. Arzneimittelforschung. 1987; 37(5): 538-41. PMID: 3040019","journal-title":"Arzneimittelforschung"},{"journal-title":"J Cardiovasc Pharmacol","author":"Orekhov,AN.","key":"ref=49","unstructured":"Orekhov AN, Baldenkov GN, Tertov VV.;et al. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol. 1988; 12(Suppl. 6): S66-8. http:\/\/dx.doi.org\/10.1097\/00005344-198812006-00017 PMID: 2468911"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0021-9150(94) 90045-0","volume":"105(2)","author":"Sobenin,IA.","year":"1994","unstructured":"Sobenin,IA.; Maksumova,MA.; Slavina,ES.; Balabolkin,MI.; Orekhov,AN. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. Atherosclerosis. 1994; 105(2): 159-63. http:\/\/dx.doi.org\/10.1016\/0021-9150(94) 90045-0 PMID: 8003091","journal-title":"Atherosclerosis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.phymed.2016.01.003","volume":"23(11)","author":"Orekhov,AN.","year":"2016","unstructured":"Orekhov,AN.; Ivanova,EA. Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential. Phytomedicine. 2016; 23(11): 1190-7. http:\/\/dx.doi.org\/10.1016\/j.phymed.2016.01.003 PMID: 26922038","journal-title":"Phytomedicine"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/07853899509031938","volume":"27(1)","author":"Orekhov,AN.","year":"1995","unstructured":"Orekhov,AN.; Tertov,VV.; Sobenin,IA.; Pivovarova,EM. Direct anti-atherosclerosis-related effects of garlic. Ann Med. 1995; 27(1): 63-5. http:\/\/dx.doi.org\/10.3109\/07853899509031938 PMID: 7742001","journal-title":"Ann Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/18722083113079990008","volume":"8(1)","author":"Orekhov,AN.","year":"2013","unstructured":"Orekhov AN, Sobenin IA, Korneev NV.;et al. Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov. 2013; 8(1): 56-66. http:\/\/dx.doi.org\/10.2174\/18722083113079990008 PMID: 23176379","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.phymed.2015.10.014","volume":"23(11)","author":"Sobenin,IA.","year":"2016","unstructured":"Sobenin,IA.; Andrianova,IV.; Lakunin,KY.; Karagodin,VP.; Bobryshev,YV.; Orekhov,AN. Anti-atherosclerotic effects of garlic preparation in freeze injury model of atherosclerosis in cholesterol-fed rabbits. Phytomedicine. 2016; 23(11): 1235-9. http:\/\/dx.doi.org\/10.1016\/j.phymed.2015.10.014 PMID: 26739249","journal-title":"Phytomedicine"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1161\/01.CIR.92.7.1758","volume":"92(7)","author":"Salonen,R.","year":"1995","unstructured":"Salonen R, Nyyss?nen K, Porkkala E.;et al. Kuopio Atherosclero-sis Prevention Study (KAPS) . A population-based primary preven-tive trial of the effect of LDL lowering on atherosclerotic progres-sion in carotid and femoral arteries. Circulation. 1995; 92(7): 1758-64. http:\/\/dx.doi.org\/10.1161\/01.CIR.92.7.1758 PMID: 7671358","journal-title":"Circulation"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00592-007-0011-x","volume":"45(1)","author":"Sobenin,IA.","year":"2008","unstructured":"Sobenin,IA.; Nedosugova,LV.; Filatova,LV.; Balabolkin,MI.; Gorchakova,TV.; Orekhov,AN. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of dou-ble-blinded placebo-controlled study. Acta Diabetol. 2008; 45(1): 1-6. http:\/\/dx.doi.org\/10.1007\/s00592-007-0011-x PMID: 17823766","journal-title":"Acta Diabetol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5551\/jat.E550","volume":"15(6)","author":"Sobenin,IA.","year":"2008","unstructured":"Sobenin,IA.; Andrianova,IV.; Demidova,ON.; Gorchakova,T.; Ore-khov,AN. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. J Atheroscler Thromb. 2008; 15(6): 334-8. http:\/\/dx.doi.org\/10.5551\/jat.E550 PMID: 19060427","journal-title":"J Atheroscler Thromb"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1476-511X-9-119","volume":"9","author":"Sobenin,IA.","year":"2010","unstructured":"Sobenin,IA.; Pryanishnikov,VV.; Kunnova,LM.; Rabinovich,YA.; Martirosyan,DM.; Orekhov,AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis. 2010; 9: 119. http:\/\/dx.doi.org\/10.1186\/1476-511X-9-119 PMID: 20958974","journal-title":"Lipids Health Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.2174\/1381612811319330014","volume":"19(33)","author":"Sobenin,IA.","year":"2013","unstructured":"Sobenin,IA.; Chistiakov,DA.; Bobryshev,YV.; Orekhov,AN. Blood atherogenicity as a target for anti-atherosclerotic therapy. Curr Pharm Des. 2013; 19(33): 5954-62. http:\/\/dx.doi.org\/10.2174\/1381612811319330014 PMID: 23438956","journal-title":"Curr Pharm Des"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s10517-006-0260-7","volume":"141(6)","author":"Nikitina,NA.","year":"2006","unstructured":"Nikitina NA, Sobenin IA, Myasoedova VA.;et al. Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med. 2006; 141(6): 712-5. http:\/\/dx.doi.org\/10.1007\/s10517-006-0260-7 PMID: 17364057","journal-title":"Bull Exp Biol Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.2174\/1381612823666170329144307","volume":"23(17)","author":"Murillo,AG.","year":"2017","unstructured":"Murillo,AG.; Fernandez,ML. The relevance of dietary polyphenols in cardiovascular protection. Curr Pharm Des. 2017; 23(17): 2444-52. http:\/\/dx.doi.org\/10.2174\/1381612823666170329144307 PMID: 28356040","journal-title":"Curr Pharm Des"},{"key":"ref=62","first-page":"491","volume":"7","author":"Sobenin,IA.","year":"2007","unstructured":"Sobenin,IA.; Myasoedova,VA.; Orekhov,AN. Antiatherogenic ac-tion of isoflavonoid-rich botanicals: an implementation for athero-sclerosis prevention in postmenopausal women. J Clin Lipidol. 2007; 7: 491","journal-title":"J Clin Lipidol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jacl.2008.08.059","volume":"2","author":"Sobenin,I.","year":"2008","unstructured":"Sobenin,I.; Myasoedova,V.; Orekhov,A. Atherosclerosis prevention in postmenopausal women with the isoflavonoid-rich dietary sup-plement Karinat. J Clin Lipidol. 2008; 2: S26-7. http:\/\/dx.doi.org\/10.1016\/j.jacl.2008.08.059","journal-title":"J Clin Lipidol"},{"key":"ref=64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081318","author":"Myasoedova,VA.","unstructured":"Myasoedova VA, Kirichenko TV, Melnichenk o AA.;et al. Anti-atherosclerotic effects of a phytoestrogen-rich herbal preparation in postmenopausal women. Int J Mol Sci. 2016; 17(8) E1318 http:\/\/dx.doi.org\/10.3390\/ijms17081318 PMID: 27529226","journal-title":"Int J Mol Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10517-007-0099-6","volume":"143(3)","author":"Gorchakova,TV.","year":"2007","unstructured":"Gorchakova,TV.; Suprun,IV.; Sobenin,IA.; Orekhov,AN. Use of natural products in anticytokine therapy. Bull Exp Biol Med. 2007; 143(3): 316-9. http:\/\/dx.doi.org\/10.1007\/s10517-007-0099-6 PMID: 18225751","journal-title":"Bull Exp Biol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1567-5688(09) 70682-8","volume":"10","author":"Gorchakova,T.","year":"2009","unstructured":"Gorchakova,T.; Myasoedova,V.; Sobenin,I.; Orekhov,A. Atheroscle-rosis preventionwith the anti-inflammatory dietary supplement In-flaminat. Atheroscler Suppl. 2009; 10: 387. http:\/\/dx.doi.org\/10.1016\/S1567-5688(09) 70682-8","journal-title":"Atheroscler Suppl"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/738679","author":"Orekhov,AN.","unstructured":"Orekhov,AN.; Melnichenko,AA.; Sobenin,IA. Approach to reduc-tion of blood atherogenicity. Oxid Med Cell Longev. 2014; 2014738679 http:\/\/dx.doi.org\/10.1155\/2014\/738679 PMID: 25101152","journal-title":"Oxid Med Cell Longev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2174\/1381612823666170102121927","volume":"23(8)","author":"Myasoedova,VA.","year":"2017","unstructured":"Myasoedova,VA.; Ivashinnikova,GA.; Sobenin,IA.; Ivanova,EA.; Orekhov,AN. Blood serum atherogenicity: Cellular test for the de-velopment of anti-atherosclerotic therapy. Curr Pharm Des. 2017; 23(8): 1195-206. http:\/\/dx.doi.org\/10.2174\/1381612823666170102121927 PMID: 28042768","journal-title":"Curr Pharm Des"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/168678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T23:22:06Z","timestamp":1662765726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/168678\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,15]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163816666190101112241","relation":{},"ISSN":["1570-1638"],"issn-type":[{"type":"print","value":"1570-1638"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}